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Acquired myasthenia is uncommon in childhood and its 
onset in the first decade of life accounts for less than 3% of all 
myasthenia gravis (MG) cases.1 Thymoma is infrequent below 
the age of 10; the association of the two diseases is exceed-
ingly rare in children.2
In September 2005, a 7-year-old boy began to complain 
of fatigable limb weakness and dysphagia. MG was diagnosed 
on the basis of positive Tensilon test, significant decrement 
(>20%) in the amplitude of the compound muscle action 
potential on deltoid muscle at low-rate repetitive nerve stimu-
lation, and increased serum acetylcholine receptor (AChR) 
antibody (8.6 nM). Treatment with oral prednisone (1mg/
kg/day) and acetylcholinesterase inhibitors was started with 
benefit. A chest computed tomography scan disclosed a large 
anterior mediastinal mass (56 × 36 mm), which was removed 
by extended thymectomy. Histological examination revealed a 
partially capsulated thymoma of B3 type,3 with perithymic fat 
invasion (Masaoka stage II)4 (Fig. 1).
Myasthenic symptoms improved and corticosteroid ther-
apy was tapered off within 6 months after surgery. one month 
later, the boy was referred to our institute for MG worsening. 
Prednisone therapy was reintroduced (1mg/kg/day), several 
courses of immunoglobulin were administered intravenously, 
and azathioprine (1.5mg/kg/day) was added. To date, 6 years after 
thymectomy, the boy, still under azathioprine and prednisone 
shows only mild facial weakness. The dose of prednisone was 
tapered to 0.3mg/kg/every other day; MG symptoms recurred 
when further tapering was attempted. Chest magnetic resonance 
imaging  and octreotide-positron emission tomography revealed 
neither local nor extramediastinal recurrences of thymoma. AChR 
antibody test was not repeated during the follow-up.
DISCUSSION
our patient had a B3-type thymoma that has never 
been described in infantile MG. These data suggest that in 
the presence of serum anti-AChR abs, a careful radiological 
investigation of the mediastinum to rule out the presence of a 
thymoma should also be done in prepubertal MG.
Surgical resection is the treatment of choice for stage-I 
and -II thymomas, whereas chemotherapy is performed in 
patients with stage-III or -IV tumors. However, therapeutic 
indications about adjuvant radiation therapy for stage-II thy-
moma are still controversial. Current indications range from 
postoperative radiation for all patients with thymoma, to 
adjuvant radiotherapy for only patients with tumors larger 
than 5 cm. A recent study suggested that complete resec-
tion alone might be sufficient for stage-II thymoma.5 In the 
absence of settled guidelines for thymoma treatment in chil-
dren, we decided not to perform adjuvant therapies. We did 
not consider chemotherapy on the basis of the low invasive-
ness of the tumor, and excluded radiotherapy for its well-
known late-local morbidity associated with mediastinal and 
lung irradiation, and for its possible side-effects on develop-
ing organs.2 However, it remains to be settled how long and 
with which modalities tumor follow-up is to be performed 
in children.
In our patient, as in most MG cases, the onset of 
muscle weakness led to the discovery of the thymic tumor. The 
association of MG and thymoma, although rare, does occur 
in the pediatric population. Corticosteroids should be slowly 
tapered after thymectomy to avoid the worsening of MG.
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FIGURE 1. Section of the tumor stained with hematoxylin 
and eosin. The epithelial cells seem large and polygonal, 
with small nucleoli. Scattered lymphocytes are present 
among the tumoral epithelial cells.
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